Phase II Randomized Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naive Metastatic Pancreatic Cancer (GIANT)
Summary
The purpose of this phase II trial is to compare two treatment combinations: gemcitabine hydrochloride and nab-paclitaxel, or fluorouracil, leucovorin calcium, and liposomal irinotecan in older patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine hydrochloride, nab-paclitaxel, fluorouracil, leucovorin calcium, and liposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This study may help doctors find out which treatment combination is better at prolonging life in older patients with metastatic pancreatic cancer.
General Information
NCT#: NCT04233866
Study ID: EA2186
Trial Phase: Phase II
Trial Sponsor: Eastern Cooperative Oncology Group (ECOG)
Therapies Used in This Trial: Nab-paclitaxel, Fluorouracil, Gemcitabine, Leucovorin, irinotecan liposome injection